4886 Stock Overview
Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
ASKA Pharmaceutical Holdings Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,100.00 |
| 52 Week High | JP¥2,720.00 |
| 52 Week Low | JP¥1,775.00 |
| Beta | 0.45 |
| 1 Month Change | 4.22% |
| 3 Month Change | -6.87% |
| 1 Year Change | 17.71% |
| 3 Year Change | 108.54% |
| 5 Year Change | 66.67% |
| Change since IPO | 0% |
Recent News & Updates
Shareholder Returns
| 4886 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 2.4% | 2.8% | 3.6% |
| 1Y | 17.7% | 12.8% | 16.3% |
Return vs Industry: 4886 exceeded the JP Pharmaceuticals industry which returned 10.7% over the past year.
Return vs Market: 4886 exceeded the JP Market which returned 15% over the past year.
Price Volatility
| 4886 volatility | |
|---|---|
| 4886 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4886 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4886's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1920 | 762 | Takashi Yamaguchi | www.aska-pharma-hd.co.jp |
ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and researches, manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices.
ASKA Pharmaceutical Holdings Co.,Ltd. Fundamentals Summary
| 4886 fundamental statistics | |
|---|---|
| Market cap | JP¥59.56b |
| Earnings (TTM) | JP¥5.98b |
| Revenue (TTM) | JP¥63.57b |
10.0x
P/E Ratio0.9x
P/S RatioIs 4886 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4886 income statement (TTM) | |
|---|---|
| Revenue | JP¥63.57b |
| Cost of Revenue | JP¥32.18b |
| Gross Profit | JP¥31.39b |
| Other Expenses | JP¥25.41b |
| Earnings | JP¥5.98b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
| Earnings per share (EPS) | 210.70 |
| Gross Margin | 49.38% |
| Net Profit Margin | 9.40% |
| Debt/Equity Ratio | 11.9% |
How did 4886 perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield21%
Payout RatioDoes 4886 pay a reliable dividends?
See 4886 dividend history and benchmarks| ASKA Pharmaceutical HoldingsLtd dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 26 2025 |
| Days until Ex dividend | 89 days |
| Days until Dividend pay date | 179 days |
Does 4886 pay a reliable dividends?
See 4886 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 12:56 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ASKA Pharmaceutical Holdings Co.,Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seohyun Lee | Citigroup Inc |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |
| Yuriko Ishida | Mizuho Securities Co., Ltd. |